About Sanofi
Funding & Growth
✓ Pros
- • Strong immunology portfolio (Dupixent)
- • Cambridge, MA hub
- • Global vaccine leader
- • Good work-life balance
- • Diverse therapeutic areas
✗ Cons
- • French headquarters (timezone)
- • Corporate restructuring
- • Large company processes
- • Some legacy systems
🏢 Working Here
Sanofi's US computational biology operations are centered in Cambridge, MA (Kendall Square - the primary US R&D hub with 500+ scientists), with additional presence in Bridgewater, NJ, and South San Francisco, CA.
The Cambridge facility serves as Sanofi's innovation engine for immunology, rare diseases, and early discovery.
Being in Kendall Square provides unmatched access to computational biology talent, MIT/Harvard/Broad Institute partnerships, and the broader Boston biotech ecosystem.
Following the 2020 Allergan acquisition, Sanofi expanded capabilities in neuroscience and ophthalmology.
Bioinformaticians work on blockbuster programs including Dupixent (IL-4/IL-13 inhibitor, >$10B revenue for atopic dermatitis/asthma), BTK inhibitors, rare disease genetics (Fabry, Gaucher, Pompe), and vaccine development.
The company has made significant AI/ML investments through partnerships with Exscientia and Owkin.
Work involves analyzing immunology trial data, rare disease patient genomics, vaccine immunology, and multi-omic biomarker development.
The Cambridge location offers access to world-class single-cell/spatial genomics facilities and regular seminars with field leaders.
🧬 Bioinformatics Focus
Sanofi computational biology spans immunology, rare diseases, and vaccines. Key areas:
- Type 2 inflammation - analyzing patient samples from Dupixent trials in atopic dermatitis, asthma, eosinophilic esophagitis, understanding IL-4/IL-13 biology through multi-omics, predicting response,
- Rare disease genetics - deep phenotyping of rare disease patients, understanding mechanisms for lysosomal storage disorders, hemophilia, rare blood disorders, gene therapy development,
- Autoimmune diseases - BTK inhibitor biomarkers for lupus and other indications, multi-omic profiling of immune cell subsets,
- Vaccine immunology - analyzing immune responses to flu, COVID, RSV vaccines, predicting immunogenicity, optimizing adjuvants,
- Oncology - analyzing BTK inhibitors in CLL, developing novel immuno-oncology approaches. Sanofi maintains unique datasets including rare disease natural history studies and vaccine trial immunology data spanning decades. The Genzyme legacy brings deep expertise in rare genetic diseases. Technical challenges include small patient cohorts for rare diseases, integrating enzyme replacement therapy outcomes with genetics, analyzing complex immune responses to vaccines, and developing biomarkers for next-gen immunology targets.
📈 Career Growth & Development
Career Paths
Scientist Track
Management Track
Compensation
Competitive US salaries with 15-18% bonuses and stock grants (Sanofi is Paris-listed). Cambridge location commands premium salaries.
Development
Extensive professional development includes training, conferences, and external collaborations. Publications are encouraged, particularly for rare disease and vaccine work.
Mobility
Internal mobility is possible between Cambridge, NJ, and international sites like Paris and Frankfurt.
Network
Global alumni network given Sanofi's international presence.
Culture
Sanofi values both scientific excellence and adaptability, with a refocus on immunology and rare diseases providing clearer strategic direction.
Growth
The immunology pipeline strength (Dupixent >$10B revenue) creates career growth opportunities, especially for computational biologists specializing in immunology, rare diseases, or vaccines.
💊 Top Medicines & Blockbuster Drugs
Dupixent (dupilumab)
2017Indication: Atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, COPD
IL-4/IL-13 inhibitor - fastest-growing biologic (Regeneron partnership)
Annual Revenue (USD)
Aubagio (teriflunomide)
2012Indication: Relapsing forms of multiple sclerosis
Oral immunomodulator - facing generics
Annual Revenue (USD)
Sarclisa (isatuximab)
2020Indication: Multiple myeloma - CD38 monoclonal antibody
Combination therapy for relapsed/refractory MM
Annual Revenue (USD)
Praluent (alirocumab)
2015Indication: High cholesterol - PCSK9 inhibitor
Cardiovascular outcomes benefit (Regeneron partnership)
Annual Revenue (USD)
Kevzara (sarilumab)
2017Indication: Rheumatoid arthritis, polymyalgia rheumatica
IL-6 receptor inhibitor (Regeneron partnership)
Annual Revenue (USD)